Reversal of direct oral anticoagulants: Highlights from the Anticoagulation Forum guideline

Link to article at PubMed

Cleve Clin J Med. 2021 Feb 1;88(2):98-103. doi: 10.3949/ccjm.88a.19133.

ABSTRACT

The 2019 guideline from the Anticoagulation Forum provides clear instructions on how to use 2 agents for reversing the effects of direct oral anticoagulants (DOACs): idarucizumab for dabigatran-associated bleeding and andexanet alfa for bleeding associated with rivaroxaban and apixaban. The guideline also discusses off-label use of andexanet alfa for bleeding associated with edoxaban and betrixaban and the use of hemostatic agents such as activated prothrombin complex concentrate and 4-factor prothrombin complex concentrate. Lastly, it offers approaches for building and managing stewardship programs at the health system level.

PMID:33526463 | DOI:10.3949/ccjm.88a.19133

Leave a Reply

Your email address will not be published.